TECX · Tectonic Therapeutic, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-30 | McNamara Peter |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. |
Common Stock
|
172 |
| 2026-06-30 | McNamara Peter |
Chief Scientific Officer |
Convert↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Employee Stock Option (Right to Buy)
|
172 |
| 2026-06-30 | McNamara Peter |
Chief Scientific Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. |
Common Stock
|
172 |
| 2026-06-20 | REICIN ALISE |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on December 4, 2024. |
Common Stock
|
924 |
| 2026-06-11 | Lochner Daniel |
Chief Financial Officer |
Award↑
Filing footnotes — Performance Stock Option (Right to Buy) (Direct)
Represents the number of shares earned under a performance-based stock option award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based conditions of the option award, the option was not reportable under Section 16 until the performance conditions were certified by the Issuer's Board of Directors, which occurred on June 11, 2026. The option reported on this form represents 50% of the total number of shares underlying the performance option subject to the option award. The remaining 50% of the shares will be earned upon the satisfaction of additional performance criteria. The shares underlying the option are fully vested and immediately exercisable as of June 1, 2026. |
Performance Stock Option (Right to Buy)
|
7,500 |
| 2026-06-09 | Vitorovic Stefan |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date. |
Stock Option (Right to Buy)
|
10,200 |
| 2026-06-09 | Tipirneni Praveen P. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date. |
Stock Option (Right to Buy)
|
10,200 |
| 2026-06-09 | Donenberg Phillip B. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date. |
Stock Option (Right to Buy)
|
10,200 |
| 2026-06-09 | SPRINGER TIMOTHY A |
Director, 10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date. |
Stock Option (Right to Buy)
|
10,200 |
| 2026-06-08 | Chutter Jessica Caroline |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-08 | Chutter Jessica Caroline |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-third (1/3) of the shares subject to the option shall vest on June 8, 2027, and the balance shall vest in 24 equal monthly installments thereafter, subject in each case to the Reporting Person providing continuous service to the Issuer on each such date. |
Stock Option (Right to Buy)
|
20,400 |
| 2026-05-04 | Ruddy Marcella K. |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. |
Common Stock
|
1,065 |
| 2026-04-01 | Nader Francois |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One Third (1/3) of the shares subject to the option shall vest on April 1, 2027, and the balance shall vest in 24 equal monthly installments thereafter, subject in each case, to the Reporting Person providing continuous service to the Issuer through each applicable vesting date. |
Stock Option (Right to Buy)
|
20,400 |
| 2026-04-01 | Ruddy Marcella K. |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. |
Common Stock
|
1,000 |
| 2026-04-01 | Nader Francois |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-03-06 | Ruddy Marcella K. |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. |
Common Stock
|
10,000 |
| 2026-03-06 | McNamara Peter |
Chief Scientific Officer |
Convert↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Received in exchange for a stock option to acquire 71,029 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017962/xslF345X05/form4-06242024_080611.xml 25% of the shares subject to the option vested on June 1, 2022; and the remainder of the shares subject to the option vest in 36 equal monthly installments with the final amount vesting on June 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Employee Stock Option (Right to Buy)
|
2,500 |
| 2026-03-06 | McNamara Peter |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. |
Common Stock
|
215 |
| 2026-03-06 | McNamara Peter |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. |
Common Stock
|
6,047 |
| 2026-03-06 | McNamara Peter |
Chief Scientific Officer |
Convert↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Employee Stock Option (Right to Buy)
|
215 |
| 2026-03-06 | McNamara Peter |
Chief Scientific Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. |
Common Stock
|
215 |
| 2026-03-06 | McNamara Peter |
Chief Scientific Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. |
Common Stock
|
2,500 |
| 2026-03-04 | Lochner Daniel |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Common Stock
|
26,500 |
| 2026-03-04 | REICIN ALISE |
Director |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Employee Stock Option (Right to Buy)
|
69,250 |
| 2026-03-04 | McNamara Peter |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. |
Common Stock
|
1,650 |
| 2026-03-04 | REICIN ALISE |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Common Stock
|
76,500 |
| 2026-03-04 | McNamara Peter |
Chief Scientific Officer |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Common Stock
|
23,000 |
| 2026-03-04 | Schwabish Marc |
Chief Business Officer |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Common Stock
|
19,500 |
| 2026-03-04 | Ruddy Marcella K. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Common Stock
|
26,500 |
| 2026-03-04 | Lochner Daniel |
Chief Financial Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Employee Stock Option (Right to Buy)
|
24,250 |
| 2026-03-04 | Ruddy Marcella K. |
Director |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Employee Stock Option (Right to Buy)
|
24,250 |
| 2026-03-04 | McNamara Peter |
Chief Scientific Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Employee Stock Option (Right to Buy)
|
21,000 |
| 2026-03-04 | Schwabish Marc |
Chief Business Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Employee Stock Option (Right to Buy)
|
17,750 |
| 2026-03-03 | McNamara Peter |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. |
Common Stock
|
1,649 |
| 2026-02-11 | REICIN ALISE |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.02 to $21.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. These shares are held by the Reicin-Boiarsky Family Trust (the "Trust"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Common Stock
(I)
|
2,500 |
| 2026-02-10 | Schwabish Marc |
Chief Business Officer |
Convert↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
Received in exchange for a stock option to acquire 170,679 shares of Tectonic common stock pursuant to that certain merger, as more specifically described in the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017972/xslF345X05/form4-06242024_080616.xml The shares subject to the option vest as to 25% of the shares on March 15, 2022 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. |
Employee Stock Option (Right to Buy)
|
4,500 |
| 2026-02-10 | Schwabish Marc |
Chief Business Officer |
Convert↑
|
Common Stock
|
4,500 |
| 2026-02-10 | Lochner Daniel |
Chief Financial Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.24 to $21.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
6,000 |
| 2026-02-04 | Lochner Daniel |
Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on February 4, 2025. |
Common Stock
|
2,077 |
| 2026-02-04 | REICIN ALISE |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on February 4, 2025. |
Common Stock
|
4,104 |
| 2026-02-04 | Ruddy Marcella K. |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on February 4, 2025. |
Common Stock
|
2,064 |
| 2026-02-04 | McNamara Peter |
Chief Scientific Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on February 4, 2025. |
Common Stock
|
1,748 |
| 2026-02-04 | Schwabish Marc |
Chief Business Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on February 4, 2025. |
Common Stock
|
1,619 |
| 2025-12-31 | REICIN ALISE |
Director |
Convert↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
Received in exchange for a stock option to acquire 63,478 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017952/xslF345X05/form4-06242024_080648.xml The shares subject to the option vested as follows: (i) 4,079 shares on June 30, 2024; (ii) 4,078 shares on July 31, 2024, (iii) 4,078 shares on August 31, 2024, (iv) 4,079 shares on September 30, 2024, (v) 4,078 shares on October 31, 2024, (vi) 1,297 shares on November 30, 2024, (vii) 4,078 shares on January 31, 2025, (viii) 4,078 shares on February 28, 2025 and (iv) 4,078 shares on March 31, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.. |
Employee Stock Option (Right to Buy)
|
10,966 |
| 2025-12-31 | REICIN ALISE |
Director |
Convert↑
|
Common Stock
|
10,966 |
| 2025-12-22 | McNamara Peter |
Chief Scientific Officer |
Convert↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
Received in exchange for a stock option to acquire 60,000 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017962/xslF345X05/form4-06242024_080611.xml The shares subject to the option vest in 48 equal monthly installments beginning on June 27, 2022, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Employee Stock Option (Right to Buy)
|
7,000 |
| 2025-12-22 | McNamara Peter |
Chief Scientific Officer |
Convert↑
|
Common Stock
|
7,000 |
| 2025-09-25 | Ruddy Marcella K. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of September 25, 2026, September 25, 2027 and September 25, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Common Stock
|
5,370 |
| 2025-09-25 | McNamara Peter |
Chief Scientific Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Employee Stock Option (Right to Buy)
|
8,260 |
| 2025-09-25 | Lochner Daniel |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of September 25, 2026, September 25, 2027 and September 25, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Please note that the total number of securities beneficially owned following the reported transaction has been corrected to reflect the correct amount. The amount reported on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on February 7, 2025 should have reflected that the total number of securities beneficially owned following the reported transaction was 22,691 shares instead of 4,617 shares. |
Common Stock
|
5,430 |